Neurocrine Biosciences, Inc. Stock News

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Presentation Joshua Schimmer Biotech Equity Research Analyst Now we're ready to get st...

SAN DIEGO , Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September. Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will present at the Cantor Global Healthcare Conference 2025 at 1:00 p.m.

SAN DIEGO , Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025.

Neurocrine (NBIX) Q2 Revenue Jumps 17%

Neurocrine Biosciences' Ingrezza still generates most of its total revenues. This is their blockbuster drug. I also believe Ingrezza is well-positioned for future growth with new label additions, and IRA price protection warrants a bullish stance. Also, Crenessity's recent launch beat expectations, and the drug is key as a long-term second growth pillar.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants n - Corporate Participant Eiry Wyn Roberts - Corporate Participant Strategic Advisor - Corporate Participant Eric S. Benevich - Chief Commercial Officer Kyle W.

Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with 664 Total New Patient Enrollment Start Forms SAN DIEGO , July 30, 2025 /PRNews...

Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO , July 15, 2025 /PRNewswire/ -- PicnicHealth , a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), the CAHtal...